/
Oncology
Gastric or Gastroesophageal Junction Adenocarcinoma
18
Pipeline Programs↗
8
Active Trials↗
12
Companies Involved↗
Gastric or Gastroesophageal Junction Adenocarcinoma is an emerging landscape with 18 programs across 12 companies. The most active players are Qilu Pharmaceutical Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Phanes Therapeutics. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 1
No programs
Phase 23
Phase 33
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
16 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 100% of 18 pipeline programs.
Analysis
Trial Status
10
clinical trials
Not yet recruiting6 · 60%
Active, not recruiting1 · 10%
Terminated1 · 10%
Recruiting1 · 10%
Completed1 · 10%
Clinical Trials
Trial Activity
10 trials
A Single-Arm, Prospective, Open-Label Clinical Study of Iparomlimab and Tuvonralimab (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Not yet recruiting·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT07828873·34 enrolled
Efficacy and Safety of Serplulimab Combined With Short-Course SOX Regimen Versus SOX Regimen Alone as Adjuvant Therapy for Potentially Immunotherapy-Responsive Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Multicenter, Randomized Controlled Trial
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07772557·108 enrolled
A Prospective, Open-Label, Single-Arm, Phase Ib/II Study of Neoadjuvant Propranolol Plus SOX Chemotherapy and Toripalimab in Patients With Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruiting·—·Preclinical·NCT07727993·49 enrolled
A Randomized, Controlled, Exploratory Phase II Study of Trastuzumab Rezetecan in Combination With Retlirafusp Alfa ± Pertuzumab as Neoadjuvant Therapy for Locally Advanced HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07716111·24 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)